NXP 200
Alternative Names: HSK-42360; HSK42360-Na; NXP-200Latest Information Update: 01 Sep 2026
At a glance
- Originator Haisco Pharmaceutical Group
- Class Antineoplastics; Small molecules
- Mechanism of Action Proto-oncogene protein B-raf inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Colorectal cancer
- Phase I Brain cancer; Solid tumours
Most Recent Events
- 12 Aug 2026 Phase-I/II clinical trials in Colorectal cancer (Combination therapy, Metastatic disease, Inoperable/Unresectable, Second-line therapy or greater) in China (PO) (NCT07790510)
- 23 Jun 2026 HSK 42360 licensed to Nuvectis in World excluding China, Hong Kong, Macau, Taiwan
- 22 Jun 2026 Pharmacokinetics, efficacy and adverse events data from phase I clinical trials in Solid tumours released by Nuvectis Pharma